High impact company profile available at BioMarket

Analysis of the acute and chronic heart failure pipeline across seven major markets.

Somaxon Pharmaceuticals (Somaxon) is a development stage pharmaceutical company engaged in in-licensing and developing proprietary product candidates for the treatment of psychiatry and neurology disorders.

Flamel Technologies SA: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal

A report that provides a detailed analysis of seven individual lifestyle drug markets through the stages of drug delivery and discovery to product launch and lifecycle management.

High impact company profile available at BioMarket

This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis.

Introgen Therapeutics (Introgen) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer. The company has been successful in developing a strong portfolio of

The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from Multiple Sclerosis (MS). With the present global population growing to an unprecedented height of 6.5 billion in 2005 and growth rate anticipated to reach 7

The pharmaceutical industry produces increasingly complex products, with reduced time-to-market windows, and stringent domestic and international regulatory and compliance requirements. Datamonitor views PLM technology as one of the most rapidly growi

A review of the key events and trends shaping the pharmaceutical industry during 2007, with analysis of the future impact on the global pharmaceutical market in 2008 and beyond.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of transplant rejection or transplantation drugs by company and by stage as well as a summary of the latest news and developments in this area.

This analysis examines the historical and forecast performance for Barr in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance. An interactive data

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology.

This analysis examines the historical and forecast performance for Genzyme in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of ulcers drugs by company and by stage as well as a summary of the latest news and developments in this area.

As the reimbursement status for the cost of hospital-acquired infections is under pressure by payors, interest in preventing these complications at the outset is growing. Nosocomial vaccines offer one route of prevention. This report assesses the clini

A new report examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology.

The Watson Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

As more healthcare providers and payers realize the benefits of telehealth, technology vendors will need to understand where opportunities exist in the telehealth market.

With key some PD drugs expected to lose patent expiration in the near-term, visiongain predicts that the entry of new products will be inevitable. But which products will be successful and how much revenue will they generate?

The Mitsubishi Tanabe Pharmaceuticals Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Provides analysis of recent events in the osteoarthritis disease area and their impact on the market. Includes an event-based, indication-specific ten year forecast of both pipeline and marketed products to 2017 in the seven major markets (7MM).

Pharmaceutical competitive intelligence (CI) helps drive decision-making processes across an organization. As a forward-thinking, proactive support function, CI influences business development and brand management, among other areas.

High impact company profile available at BioMarket

The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; C

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of chronic obstructive pulmonary disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

Iomai Corporation: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

This analysis examines the historical and forecast performance for Forest in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale